Results 101 to 110 of about 591 (191)
First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. [PDF]
ESMO OpenNaing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. +9 moreeuropepmc +1 more sourceA Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. [PDF]
Br J Cancer, 2023 Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J. +13 moreeuropepmc +1 more sourceDramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. [PDF]
Curr OncolWilliamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, Cannon DM, Haaland B, Schroeder JD, Nix DA, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S. +18 moreeuropepmc +1 more sourceNeoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. [PDF]
Nat CancerKendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Chmielowski B, Khushalani NI, Markowitz J, Monroe M, Contreras CM, Bowles T, Norman K, Medina E, Gonzalez CR, Baselga-Carretero I, Garcilazo IP, Vega-Crespo A, Chen JM, Deen NNA, Patel SP, Grossmann KF, Sondak VK, Sharon E, Moon J, Wu MC, Ribas A. +32 moreeuropepmc +1 more sourceNetwork-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance. [PDF]
Clin Cancer ResLiu J, Farrow M, Hsing SS, Cosman R, Lemech CR, Teng C, Pal A, Nindra U, Parsonson AO, Park JJW, Rodrigues A, Chan WY, Wei J, Cohen J, Underhill CR, Brungs D, Hui M, Nagrial A, Jain S, Joshua AM. +19 moreeuropepmc +1 more sourcePamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. [PDF]
Br J Cancer, 2023 Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. +14 moreeuropepmc +1 more sourceIPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors. [PDF]
Cancer Res CommunPowderly J, Imbimbo M, Italiano A, Martin-Romano P, McKean M, Macarulla T, Castañón Alvarez E, Carneiro BA, Mager R, Barnhart V, Eck S, Murtomaki E, Loembé AB, He Y, Cooper ZA, Tu E, Fan C, Boyer Chamard A, Paturel C, Fraenkel PG, Hollebecque A. +20 moreeuropepmc +1 more sourcePhase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. [PDF]
J Clin OncolSharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimbourg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D. +25 moreeuropepmc +1 more sourceThe Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. [PDF]
Cancer Res Commun, 2023 Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. +19 moreeuropepmc +1 more source